The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2020 | SWOG 1211: Phase II trial of RVD with elotuzumab for myeloma

Name: SWOG 1211: Phase II trial of RVD with elotuzumab for myeloma
Uploaded: 2020-05-27T00:00:00Z
Duration: 4 min 54 s
Description: Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, discusses primary analysis of the randomized Phase II trial of bortezomib, lenalidomide and dexamethasone (RVD) with/without elotuzumab for newly diagnosed, high-risk multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Saad Usmani • 27 May 2020

EHA 2020

Multiple Myeloma Antibodies Bortezomib Dexamethasone Elotuzumab Lenalidomide

SWOG 1211

Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, discusses primary analysis of the randomized Phase II trial of bortezomib, lenalidomide and dexamethasone (RVD) with/without elotuzumab for newly diagnosed, high-risk multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).